randomPost

Secondary prevention of cardiovascular disease: Aspirin Cardio is the first lifesaver

Even today, after more than 120 years of history, aspirin cardio remains the mainstay of secondary prevention in patients who have had a cardiovascular disease such as stroke or heart attack.

Secondary prevention of cardiovascular disease: Aspirin Cardio is the first lifesaver

Stroke or heart attack The role of aspirin heart

The study showed that thienopyridines, antiplatelet drugs capable of inhibiting P2Y12 activity, do not offer significant benefits over cardio aspirin, which thus remains the antiplatelet drug of choice for secondary prevention of cardiovascular disease.

A meta-analysis was performed on 9 trials over the past 30 years that directly compared Cardio-aspirin with new antiplatelet drugs in more than 30,000 patients.

“All patients in secondary prevention should take an antiplatelet drug.

We tried to answer the question whether these new antiplatelet drugs give benefits compared to aspirin heart, focusing on endpoints that are very important for the patient, ie the effect on mortality and the risk of new heart attack or stroke” - explains the study coordinator, Professor Giulio Stefanini, Cardiologist at Humanitas and Professor at Humanitas University -.

The results showed that the benefits of treatment with thienopyridine are marginal compared to those with heart disease and aspirin.

“To prevent a single myocardial infarction, we would need to treat 244 patients with the new antiplatelet agents, which is too many to justify the new treatment as an alternative to aspirin heart rate,” Stefanini continues, “moreover without any effect on the risk of death.”

Comments
No comments
Post a Comment